Statistics for Travere Therapeutics, (id:6447 TVTX)

Valuation metrics

Market cap

1.54B

Enterprise value

1.51B

Trailing P/E (ttm)

-12.17

Forward P/E

-14.52

PEG ratio

-14.52

Price/Sales (ttm)

7.58

Price/Book (mrq)

-46.69

Enterprise Value/Revenue

7.41

Enterprise Value/EBITDA

-6.32

Overview

Shares outstanding

87.03M

Float

57.87M

Shares short

7.99M

% Held by insiders

0.01%

% Held by institutions

0.98%

Average volume (10 days)

1.52M

Average volume (90 days)

Price summary

52-Week low

5.12

52-Week high

20.33

52-Week change

67.73%

Beta

0.70

50-Day moving average

16.27

200-Day moving average

9.97

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-172.75%

Operating margin

-89.07%

Operational effectiveness

Return on assets

-26.14%

Return on equity

-279.94%

Income statement

Revenue (ttm)

2.63

Revenue per share (ttm)

2.63

Quarterly revenue growth (yoy)

Gross profit (ttm)

133.79M

EBITDA

-238,736,992.00

Net income to common (ttm)

-348,958,016.00

Diluted EPS (ttm)

-4.52

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

277.44M

Total cash per share (mrq)

3.56

Total debt (mrq)

402.43M

Total Debt/Equity (mrq)

-13.21

Current ratio (mrq)

170.90%

Book value per share (mrq)

-0.39

Cash flow

Cash flow statement

-272,228,000.00

Levered free cash flow (LFCF)

-214,687,872.00